In August, Swiss pharmaceutical company Rochethat it was entering a collaboration and license agreement with California-based Poseida to develop treatments for hematologic malignancies, or cancers that affect blood, bone marrow, and lymph nodes. The deal offered Poseida a $110 million payment, with up to an additional $110 million pending future milestones.
Cantor Fitzgerald analysts said those deals signal good news for smaller companies that offer similar valuable assets. They named three companies in particular that they said are"fundamentally undervalued" and could be ripe for a takeout:
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: